Lido Advisors’s ImmunityBio IBRX Stock Holding History

Lido Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-111,100	Closed	-$220K	–	2031
2025 Q4	$220K	Hold	111,100	–	–	﹤0.01%	1722
2025 Q3	$273K	Hold	111,100	–	–	﹤0.01%	1534
2025 Q2	$293K	Buy	+111,100	New	+$299K	﹤0.01%	1356

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lido Advisors's IBRX Position: Q1 2026 in Review

Lido Advisors reduced its ImmunityBio (IBRX) stake by 56% in Q1 2026, selling an estimated $120K and leaving 13,784 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Lido Advisors first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Lido Advisors held 13,784 shares of ImmunityBio worth $106K as of Q1 2026.
Lido Advisors sold 17,465 ImmunityBio shares in Q1 2026, an estimated $120K.
ImmunityBio made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1850 holding.
Lido Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.